Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly, Zydus Cadila Launch R&D Pact
by Jean-François Tremblay
April 6, 2009
| A version of this story appeared in
Volume 87, Issue 14
Zydus Cadila and Eli Lilly & Co. will collaborate to discover drugs in a program lasting up to six years. Lilly will provide Zydus with a new cardiovascular disease target. In turn, Zydus will conduct initial drug discovery work, lead identification and optimization, and preclinical studies and clinical trials up to Phase II. Lilly has rights to license any of the resulting molecules. It will pay Zydus as much as $300 million in milestones and royalties if a product is successfully launched. Lilly has similar agreements with Shanghai's Hutchison MediPharma and India's Piramal Healthcare.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X